07 April 2015
The aim of this study was to evaluate the effects of calcium channel blocker (CCB) amlodipine (AML), platelet rich plasma (PRP), and a mixture of both materials on bone healing.
Fifty-six male Wistar rats were randomly divided into four groups: group A, tibia defect model with no treatment; group B, tibia defect model treated with AML, 0.04 mg daily by oral gavage; group C, tibia defect model treated with local PRP; group D, tibia defect model treated with local PRP and AML, 0.04 mg daily by oral gavage.
At day 21, bone healing was significantly better in groups C and D compared to group A ( P<0.05), but comparisons showed no statistically significant difference in group B ( P>0.05). At day 30, groups B and C showed no statistically significant difference ( P>0.05) compared to group A, but bone healing in group D was significantly better than in group A ( P<0.05). Statistically, AML did not affect alkaline phosphatase (ALP) activity at 21 and 30 days ( P>0.05), but PRP and AML + PRP increased ALP activity statistically ( P<0.05).